Application of multivariate anova and generalized desirability to optimize the composition and technology of tablets containing N-benzyl-N-methyl-1-phenylpyrrolo [1,2-a] pyrazine-3-carboxamide

封面

如何引用文章

详细

The creation of drugs with an anxiolytic activity, which do not have the main side effects characteristic of drugs of this group, is an important and socially significant task. For its implementation, within the framework of the development of an original drug with an anxiolytic activity, the composition and manufacturing of GML-1 tablets (N-benzyl-N-methyl-1-phenylpyrrolo [1,2-a] pyrazine-3-carboxamide) are being developed.

The aim of this article is to study, using a four-factor analysis of variance, the influence of composition factors on the manufacturing properties of GML-1 tablets and the selection of the type, the amount, stage of the disintegrant addition and the type of lubricating excipients used in the technology of wet granulation of GML-1 tablets.

Materials and methods. The materials used are: the substance – GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo [1,2-a] pyrazine-3-carboxamide). Excipients: microcrystalline cellulose 101 (MCC 101); polyvinylpyrrolidone (PVP); crospovidone, croscarmellose sodium (CCS), sodium starch glycolate (SSG); magnesium stearate (MS), sodium stearyl fumarate (SSF). To obtain tablet mixtures, wet granulation and tableting with the study of their main pharmaceutical and technological properties was used.

Results. Model compositions were developed and their pharmaceutical and technological properties were studied. These results have been analyzed, the degree of these factors’ influence and their interactions have been determined. In most of the cases considered, the interactions of the factors did not cause a significant change in the optimization criteria. With an increase in the amount of a disintegrant, the disintegration time decreased unevenly, so an increase in the amount of these excipients from 4 to 6 mg had a stronger effect than from 2 to 4 mg. Factor B affected the release degree non-linearly. Factor A influenced all the optimization criteria considered, especially a PS release. The best release and disintegration were observed with crospovidone, which was of a particular importance when processing the test results using a generalized desirability method.

Conclusion. In view of the conflicting variance analysis results, for particular factors, the resulting values were additionally analyzed using the generalized desirability function. The use of this method made it possible to reduce the conflicting variance analysis results to the most optimal composition.

Abbreviations: MP – medicinal product; DP – drug product; DF – dosage form; PS – pharmaceutical substance; API – active pharmaceutical ingredient; PVP – polyvinylpyrrolidone; MCC – microcrystalline cellulose; SCC – sodium croscarmellose; SSG – sodium starch glycolate; MS – magnesium stearate; SSF – sodium stearyl fumarate; GPM – General Pharmacopoeia Monograph.

作者简介

Sergey Tishkov

Research Institute of Pharmacology n.a. V.V. Zakusov

Email: sergey-tishkov@yandex.ru
ORCID iD: 0000-0002-8321-6952

Candidate of Sciences (Pharmacy), Senior Researcher of the Laboratory of Finished Dosage Forms

俄罗斯联邦, 8, Baltiyskaya St., Moscow, 125315

Evgeniya Blynskaya

Research Institute of Pharmacology n.a. V.V. Zakusov

Email: mrsaureussnape@yandex.ru
ORCID iD: 0000-0002-9494-1332

Doctor of Sciences (Pharmacy), Head of the Laboratory of Finished Dosage Forms

俄罗斯联邦, 8, Baltiyskaya St., Moscow, 125315

Konstantin Alekseev

Research Institute of Pharmacology n.a. V.V. Zakusov

Email: convieck@yandex.ru
ORCID iD: 0000-0003-3506-9051

Doctor of Sciences (Pharmacy), Professor, Chief Researcher of the Laboratory of Finished Dosage Forms

俄罗斯联邦, 8, Baltiyskaya St., Moscow, 125315

Viktor Alekseev

Research Institute of Pharmacology n.a. V.V. Zakusov

Email: conwieck@yandex.ru
ORCID iD: 0000-0003-3542-0024

Junior Researcher of the Laboratory of Finished Dosage Forms

俄罗斯联邦, 8, Baltiyskaya St., Moscow, 125315

Dmitry Gavrilov

Research Institute of Pharmacology n.a. V.V. Zakusov

编辑信件的主要联系方式.
Email: dimagavrilov@list.ru

Junior Researcher of the Laboratory of Finished Dosage Forms

俄罗斯联邦, 8, Baltiyskaya St., Moscow, 125315

参考

  1. Korabelnikova EA. Sovremennyj podhod k diagnostike i terapii trevozhnyh rasstrojstv [Modern approach to the diagnosis and therapy of anxiety disorders]. Therapy. 2018; 7(8): 63–8. doi: 10.18565/therapy.2018.7-8.63-68. Russian
  2. Seredenin SB, Mokrov GV, Gudasheva TA, Deeva OA, Yarkov SA, Yarkova MA, Zherdev VP, Alekseev KV, Durnev AD, Neznamov GG. 1-Aril-pirollo[1,2-a] pirazin-3-karboksamidy s nejrotropnoj aktivnost’yu [1-Aryl-pyrollo [1,2-a] pyrazine-3-carboxamides with neurotropic activity]. Patent No.2572076 (2014). Priority date: 03/26/2014. Russian
  3. Seredenin SB, Yarkova MA, Povarnina PYu, Mokrov GV, Gudasheva TA. Ligandy translokatornogo belka TSPO, obladayushchie antidepressivnoj i nootropnoj aktivnost’yu [TSPO translocator protein ligands with antidepressant and nootropic activity]. Patent No. RU 2699568 C2 (2019). Priority date: 12/21/2015. Russian
  4. Yarkov SA, Mokrov GV, Gudasheva TA, Yarkova MA, Seredenin SB. Pharmacological study of new compounds – regulators of 18 kDa translocator protein. Experimental and Clinical Pharmacology. 2016; 79(1): 7–11. doi: 10.30906/0869-2092-2016-79-1-7-11. Russian
  5. Zhang MR, Kumata K, Maeda J, Yanamoto K, Hatori A, Okada M, Higuchi M, Obayashi S, Suhara T, Suzuki K. 11C-AC-5216: a novel PET ligand for peripheral benzodiazepine receptors in the primate brain. J Nucl Med. 2007 Nov;48(11):1853–61. doi: 10.2967/jnumed.107.043505.
  6. Yarkova MA, Mokrov GV, Gudasheva TA, Seredenin SB. Anksioliticheskoe dejstvie original’nyh proizvodnyh pirrolo [1, 2-a] pirazina, ligandov TSPO, zavisit ot biosinteza nejrosteroidov [Anxiolytic action of the original derivatives of pyrrolo [1, 2-a] pyrazine, TSPO ligands, depends on the biosynthesis of neurosteroids]. Chemical and Pharmaceutical Journal. 2016; 50(8): 3–6. doi: 10.30906/0023-1134-2016-50-8-3-6. Russian
  7. Yarkova MA, Povarnina PYu, Mokrov GV, Gudasheva TA, Seredenin SB. Antidepressivnyj i nootropnyj effekty original’nyh ligandov translokatornogo belka TSPO [Antidepressant and nootropic effects of the original ligands of the TSPO translocator protein]. Experimental and Clinical Pharmacology. 2017; 80 (4): 3–7. doi: 10.30906/0869-2092-2017-80-4-3-7. Russian
  8. Novitsky AA, Bochkov PO, Shevchenko RV, Gribakina OG, Litvin AA, Kolyvanov GB, Kolyvanov GB, Zherdev VP, Mokrov GV, Gudasheva TA, Yarkova MA, Seredenin SB. Farmakokinetika potencial’nogo anksiolitika GML-1 u krys [Pharmacokinetics of the potential anxiolytic GML-1 in rats]. Experimental and Clinical Pharmacology. 2018; 81 (6): 24–28. doi: 10.30906/0869-2092-2018-81-6-24-28. Russian
  9. Yudina DV, Blynskaya EV, Alekseev KV. Razrabotka sostava tabletok GML-1, poluchennyh metodom vlazhnogo granulirovaniya: vybor napolnitelya i svyazuyushchego [Development of the composition of GML-1 tablets obtained by wet granulation: the choice of filler and binder]. Pharmacy. 2018.; 67(3): 35–40. doi: 10.29296/25419218-2018-03-07. Russian
  10. Yarkova MA, Blynskaya EV, Yudina DV, Mokrov GV, Gudasheva TA, Alekseev KV. Razrabotka i ocenka anksioliticheskogo dejstviya tabletirovannoj lekarstvennoj formy GML-1 [Development and evaluation of the anxiolytic action of the tablet dosage form GML-1]. Chemical and pharmaceutical journal. 2019; 53 (4): 39–43. doi: 10.30906/0023-1134-2019-53-4-39-43. Russian
  11. Gaevaya LM, Grushevskaya LN, Sergeeva MS, Dudenkova ME, Avdyunina NI, Pyatin BM. Razrabotka metodiki opredeleniya pokazatelya “Rastvorenie” dlya tabletok novogo soedineniya s anksioliticheskoj aktivnost’yu GML-1 [Development of a method for determining the “Dissolution” index for tablets of a new compound with anxiolytic activity GML-1]. Experimental and Clinical Pharmacology. 2018; 81 (5s): 50–50a. doi: 10.30906/0869-2092-2018-81-5s-50-50a. Russian
  12. Gaevaya LM, Grushevskaya LN, Sergeeva MS, Illarionov AA, Avdyunina NI, Pyatin BM, Bayburtskiy FS, Mokrov GV. Fiziko-himicheskie svojstva i razrabotka metodik analiza substancii novogo original’nogo anksioliticheskogo preparata GML-1 [Physicochemical properties and development of methods for analyzing the substance of the new original anxiolytic drug GML-1]. Chemical and pharmaceutical journal. 2018; 52(9): 43–8. doi: 10.30906/0023-1134-2018-52-9-43-48. Russian
  13. Yudina DV, Blynskaya EV, Alekseev KV, Minaev SV, Marakhova AI. Farmacevticheskaya razrabotka-instrument kontrolya kachestva original’nogo lekarstvennogo sredstva s anksioliticheskim dejstviem [Pharmaceutical development-instrument for quality control of the original drug with anxiolytic action]. Pharmacy. 2018; 67(8): 27–36. doi: 10.29296/25419218-2018-08-05. Russian
  14. Blynskaya EV, Tishkov SV, Alekseev KV, Minaev SV, Alekseev VK. Primenenie dispersionnogo analiza s cel’yu podbora vspomogatel’nyh veshchestv dlya polucheniya liofilizirovannyh tabletok GK-2 [The use of analysis of variance for the selection of excipients for obtaining lyophilized tablets GK-2]. Vestnik VSU. Series Chemistry. Biology. Pharmacy. 2019; (1):117–26. Russian
  15. Khoshvaght H, Delnavaz M, Leili M. Optimization of acetaminophen removal from high load synthetic pharmaceutical wastewater by experimental and ANOVA analysis. Journal of Water Process Engineering. 2021; 42:102–7. DOI: 10.1016 / J.JWPE.2021.102107
  16. Rashwan SS, Abdelkader B, Abdalmonem A, Abou-Arab TW, Nemitallah MA, Habib MA, Ibrahim AH. Experimental and Statistical ANOVA Analysis on Combustion Stability of CH4/O2/CO2 in a Partially Premixed Gas Turbine Combustor.” ASME. J. Energy Resour. Technol. 2022; 144(6): 062301. doi: 10.1115/1.4051755.
  17. Blynskaya E, Tishkov S, Alekseev K, Povarnina P, Marakhova A, Sachivkina N. Development and optimization of the lyophilized tablets containing a dipeptide mimetic of the Nerve Growth Factor using the desirability function and analysis of variance (ANOVA). International Journal of Pharmaceutical Research. 2020;12: 925–40. doi: 10.31838/ijpr/2020.SP1.14.
  18. Wu J, Jiang Z, Wan L, Song H, Abbass K. Robust Optimization for Precision Product using Taguchi-RSM and Desirability Function. Arabian Journal for Science and Engineering. 2021; 46(3): 2803–14. doi: 10.1007/s13369-020-05326-4.
  19. D’Addona DM., Raykar SJ, Singh D, Kramar D. Multi Objective Optimization of Fused Deposition Modeling Process Parameters with Desirability Function. Procedia CIRP. 2021; (99): 707–10. doi: 10.1016/j.procir.2021.03.117.
  20. Blynskaya EV, Tishkov SV, Alekseyev KV, Minaev SV Creation of loophilisate of GK-2 for preparation of solution for injections with use of polyols. Drug Development & Registration. 2018;(2):26–31. Russian
  21. Dadhich M, Prajapati OS, Sharma V. Investigation of boiling heat transfer of titania nanofluid flowing through horizontal tube and optimization of results utilizing the desirability function approach. Powder Technology. 2021; 378: 104–23. doi: 10.1016/j.powtec.2020.09.077.
  22. Castillo DE, Montgomery DC, McCarville DR. Modified Desirability Functions for Multiple Response Optimization. Journal of Quality Technology. 1996;28(3):337–45. doi: 10.1080/00224065.1996.11979684.
  23. Costa NR, Lourenço J, Pereira ZL. Desirability function approach: a review and performance evaluation in adverse conditions. Chemometrics and Intelligent Laboratory Systems. 2011; 107(2): 234–44. doi: 10.1016/j.chemolab.2011.04.004.
  24. Ganeshpurkar A, Pandey V, Asati S, Maheshwari R, Tekade M, Tekade RK. Experimental Design and Analysis of Variance. Dosage Form Design Parameters. Academic Press; 2018: 281–301. doi: 10.1016/B978-0-12-814421-3.00008-7.

补充文件

附件文件
动作
1. JATS XML
2. Figure 1 - Structural formula of GML-1

下载 (25KB)
3. Figure 2 – Graph of the influence of the main factors effects on the average values of tablets GML-1 resistance to crushing

下载 (55KB)
4. Figure 3 – Graph of the factors influence on the average values of GML-1 tablets disintegration

下载 (55KB)
5. Figure 4 – Graph of the main influence effects of particular factors on the average kinetics values of the GML-1 tablets dissolution

下载 (52KB)

版权所有 © Tishkov S.V., Blynskaya E.V., Alekseev K.V., Alekseev V.K., Gavrilov D.I., 2022

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 
##common.cookie##